

Precision Medicine in Solid Tumors

Guest Editors:

Dr. Nandini Dey

Senior Scientist & Director,
Translational Oncology
Laboratory, Avera Cancer
Institute, Sioux Falls, SD, USA

Dr. Pradip De

1. Senior Scientist, Translational
Oncology Laboratory, Avera
Cancer Institute, Sioux Falls, SD,
USA
2. Consultant, VieCure,
Greenwood Village, CO, USA


Deadline for manuscript
submissions:

closed (31 August 2021)

Message from the Guest Editors

Precision medicine and personalized medicine are terms of the future of oncology. The conception and evolution of these two terms in translational research, as well as in successful clinical care in oncology, owes heavily to the technological revolution, which provided comprehensive genomic data in the post-human genome project era. While we are approaching a more optimistic future of clinical medicine empowered with the knowledge of “exactly targeting” the signaling in the tumor cell that caused its oncogenic transformation (Precision) in a particular patient in a specific time point (Personalised), we are still far from the finish line. The challenges are the enormity and legality of the data and the limited translation of knowledge to patient outcomes. Have we reached the saturation point for finding a new effective-target in oncology? Can immune-target(s) work synergistically with molecularly-driven targets in achieving a comparatively favorable outcome in clinical trials? Nonetheless, we have enthusiasm and perseverance from the research and clinical communities.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI